

BC CANCER REB REPORT

2025

This report provides annual statistics for the achievements of the BC Cancer Research Ethics Board and Office.

Full Board Review

NEW APPLICATIONS REVIEWED

85

(+3.7% from 82 applications in 2024)

Highlights:

- Top sponsor: CCTG (6)
- Top for-profit sponsor: Janssen (3)
- Number of local Investigator-Initiated Studies (IIS): 18 (+38% from 13 IIS in 2024)


New applications by sponsor



Academic or Cooperative

35


(+13% from 31 applications in 2024)




For-Profit

50

(-2% from 51 applications in 2024)




New applications by month



*No new application in December due to REB Workshop

New applications by submitting centre




- VANCOUVER**
 - BC Cancer Vancouver (59)
 - Leukemia/BMT Program (4)
 - Vancouver Prostate Centre (2)
 - University of British Columbia (1)
 - Lion's Gate Hospital (1)
 - VGH (2)
- KELOWNA**
 - BC Cancer Kelowna (5)
- VICTORIA**
 - BC Cancer Victoria (4)
- PRINCE GEORGE**
 - BC Cancer Prince George (3)
- SURREY**
 - BC Cancer Surrey (2)
- ABBOTSFORD**
 - BC Cancer Abbotsford (2)

- Highlights:**
 - 79% increase in BC Cancer Vancouver submissions (33 in 2024)
 - BC Cancer Prince George submitted 3 applications (0 in 2024)
 - 73% decrease in submissions from BMT Program (15 in 2024)

New applications by intervention

Interventional: 76


Non-Interventional: 9



*Other: surgery, exercise, CAR-T, fecal transplant




Highlights (compared to 2024):

- 7% increase in drug intervention
- 71% increase in radiation intervention
- Three new biobanks approved



<http://www.bccancer.bc.ca/our-research/ethics-oversight/researchethics>

Full Board Review



FULL BOARD DECISIONS

- 94%** Approve with Provisos
- 6%** Deferral* (Doubled compared to 2024)
- 0%** Disapproval

* Breakdown (status as of 09 Apr 2026)

- 2 applications were withdrawn by the For-Profit Sponsor (during provisos)
- 5 deferred applications: 3 applications were revised; 1 application was inactivated and submitted under a new application number; 1 application was revised and qualified for minimal risk review

Post-Approval Activities (PAAs)

Total
306
(+7.4% from 285 in 2024)

Amendments
159
(unchanged from 2024)

Annual Renewals
147
(+16.7% from 126 in 2024)

Monthly Activity

Month	Amendments	Annual Renewals
Jan	20	7
Feb	16	16
Mar	9	10
Apr	18	13
May	10	17
Jun	8	17
Jul	13	6
Aug	16	19
Sep	13	16
Oct	15	12
Nov	12	10
Dec	9	4

Minimal Risk (Delegated) Review

New Minimal Risk Applications

Total received:

234


(+17% from 200 applications in 2024)

Total approved:

*Does not include applications transferred to or from other REBs

207

(+7.3% from 193 applications in 2024)




Submissions requiring AI review:

16


*One application reviewed by Full Board
**26% decrease in reviews from 2024 (19)

Timeline to Approval



Number of days from PI submission to REB approval
Current status:
2025: 10 approved, 4 pending provisos,
1 withdrawn, 1 inactivated

Minimal Risk Post-Approval Activities



Accomplishments and Updates


NEW

- RISE Clinical Survey Page (March 2025)
- Automatic Termination of REB Applications Greater than 365 Days (June 2025)
- Memo: Submission of Periodic Safety Line Listing Reports (July 2025)

UPDATED

- Clinical ICF Template (July 2025)
- RISE Clinical Annual Renewal PAA Coversheet (September 2025)

- February: Applied for SRCR SETS grant
- March: Presentation at Canadian Association of Research Ethics Boards (CAREB) annual conference
- April - November: CanReview Tactical Working Groups
- May: Research Challenge 1:1 consultations
- June: Chair and Vice-Chair transition
- June: Applied for BC Cancer Summit session
- September: REB Office staff transition
- September: Research Challenge RISE Tutorial
- November: BC Cancer Summit
- December: Annual REB Workshop



REB Membership & Office Staff

WELCOME ✨ to the TEAM

REB Administrator:

- **Jessica Morrice** (return from leave)

Voting members:

- **Saroj Niraula** (Medical oncologist)
- **Srinivas Raman** (Radiation oncologist)
- **Abdulla AL-Rashdan** (Radiation oncologist)
- **Thomas Kennedy** (Radiation oncologist)
- **Jennifer Warriner** (Ethicist)
- **Vincent Poon** (Medical oncologist)
- **Corinne Maurice-Dror** (Medical oncologist)
- **Anna Hayden** (Hematologist - return from leave)

Ad hoc members:

- **Lisa Tang** (AI/Computer Science/Pathology)

REB Chair:

- **Howard Lim** (Medical oncologist)

REB Vice Chair:

- **Anna Tinker** (Medical oncologist)



REB Chair:

- **Karen Gelmon** (Medical oncologist)

REB Vice Chair:

- **Vivien Bramwell** (Medical oncologist)

Voting members:

- **Matthew Chan** (Radiation oncologist)
- **Jack Zhang** (Radiation oncologist)
- **Hamid Raziee** (Radiation oncologist)
- **Julie Gibson** (Legal)

THANK YOU!

Ad hoc members:

- **Beth Payne** (AI/Digital health systems)

REB Administrator:

- **Melissa Riding**